HAMBURG (dpa-AFX) - Evotec AG (EVTCY.PK, EVOTF.PK) Thursday said it has entered into a multi-target screening collaboration on several ion channel targets, with Asahi Kasei Pharma Corp., a wholly owned subsidiary of Japan-based Asahi Kasei Corp. Financial terms were not disclosed.
Under the terms of the agreement, Evotec will use its world-class ion channel platform to identify inhibitors of multiple ion channel targets.
Dr Mario Polywka, Chief Operating Officer of Evotec, stated: '...Our expertise and platform on ion channel drug discovery has proven to add significant value to our partner's programmes and we look forward to supporting Asahi Kasei Pharma in their own ion channel drug discovery efforts.'
Copyright RTT News/dpa-AFX